Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 4/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.44 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.37 |
| ▸ | KDM4A | O75164 | 2/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | RBP4 | P02753 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986385 | 0.93 | BRD4 (0.43) | KDM5AKDM4CKMOBRD4KDM2B | |
| SCHEMBL983478 | 0.89 | KMO (0.39) | KDM5AKDM4CKMOKDM4ARBP4 | |
| SCHEMBL983088 | 0.88 | JAK3 (0.46) | KDM5AKDM4C | |
| SCHEMBL981956 | 0.87 | PDE4A (0.38) | KDM5AKDM4CKMOKDM4A | |
| SCHEMBL3429999 | 0.87 | KDM4E (0.43) | KDM5AKDM4CKMOKDM4A | |
| SCHEMBL985069 | 0.86 | KDM4C (0.38) | KDM5AKDM4CKMOKDM4A | |
| SCHEMBL984646 | 0.85 | ACKR3 (0.41) | KDM5AKDM4CSCN8ASCN10A | |
| SCHEMBL983554 | 0.85 | KDM4C (0.39) | KDM5AKDM4CKMOKDM4APIK3R1 | |
| SCHEMBL982755 | 0.85 | KDM4C (0.39) | KDM5AKDM4CKMOKDM4APIK3R1 | |
| SCHEMBL981859 | 0.84 | SMYD3 (0.41) | KDM5AKDM4CSCN8ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | claimed |
| CN-101959890-B | Pyrrolopyrimidine carboxamides | NYCOMED GMBH | 2013-10-30 | — | — | CN | disclosed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| CN-101959890-A | Pyrrolopyrimidine carboxamides | NYCOMED GMBH | 2011-01-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | KDM5A 263/4885KDM4C 599/4885KMO 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.